Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Navicare Biotech Co's Enterprise Value is NT$1,498.3 Mil.
Navicare Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-3.3 Mil. Therefore, Navicare Biotech Co's EV-to-FCF for today is -457.77.
The historical rank and industry rank for Navicare Biotech Co's EV-to-FCF or its related term are showing as below:
ROCO:8472'
s EV-to-FCF Range Over the Past 10 Years
Min: -517.38 Med: -2.6 Max: 17.15
Current: -465.36
During the past 13 years, the highest EV-to-FCF of Navicare Biotech Co was 17.15. The lowest was -517.38. And the median was -2.60.
ROCO:8472's EV-to-FCF is ranked worse than 100% of 772
companies
in the Retail - Cyclical industry
Industry Median: 13.735
vs ROCO:8472: -465.36
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Navicare Biotech Co (ROCO:8472) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Navicare Biotech Co's PE Ratio (TTM) for today is calculated as:
Navicare Biotech Co's share price for today is NT$79.00.
Navicare Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Navicare Biotech Co EV-to-FCF Related Terms
Navicare Biotech Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Navicare Biotech Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8472 vs AMZN, BABA, PDD: EV-to-FCF Comparison
For the Internet Retail subindustry, Navicare Biotech Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navicare Biotech Co EV-to-FCF vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Navicare Biotech Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Navicare Biotech Co's EV-to-FCF falls into.
Navicare Biotech Co's current Enterprise Value is NT$1,498.3 Mil.
Navicare Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-3.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navicare Biotech Co (ROCO:8472) has a EV-to-FCF of -457.77 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Navicare Biotech Co and its competitors. According to the industry distribution chart, Navicare Biotech Co ranks #999999 out of 772 companies in the Retail - Cyclical industry.
Is Navicare Biotech Co's EV-to-FCF too high?
Navicare Biotech Co's current EV-to-FCF is -457.77. Based on the distribution chart, Navicare Biotech Co ranks #999999 out of 772 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Navicare Biotech Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Navicare Biotech Co's EV-to-FCF compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Navicare Biotech Co ranks #999999 out of 772 companies for EV-to-FCF. This places Navicare Biotech Co in the lower half of its industry. The industry median EV-to-FCF is 13.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Retail - Cyclical company?
The median EV-to-FCF among Retail - Cyclical companies is 13.74, based on 772 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Navicare Biotech Co and its competitors. For the Retail - Cyclical industry, the median EV-to-FCF is 13.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navicare Biotech Co's current EV-to-FCF is -457.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navicare Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Navicare Biotech Co (ROCO:8472) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$44.21, compared to a current price of NT$79.00 — trading 78.7% above its estimated fair value. The current EV-to-FCF is -457.77. Navicare Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Navicare Biotech Co (ROCO:8472), the current EV-to-FCF is -457.77 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?
Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued.
The current stock price of NT$79.00 is trading 78.7% above its estimated GF Value™ of NT$44.21.
GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.
Key valuation signals for ROCO:8472:
EV-to-FCF: -457.77
GF Value™: NT$44.21 vs. price of NT$79.00 (78.7% above fair value)
No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8472 has been successfully added to your 
